AttendMe Owl Logo
AttendMe
Sign In
All Pathways
Hematology & OncologyEmergency

Anticoagulation Reversal for Major Bleeding (ISTH 2025)

Anticoagulation Reversal for Major Bleeding (ISTH 2025): Major Bleeding on Anticoagulant → Identify Anticoagulant → Warfarin (VKA) → Supportive Care (Al...

Pathway Overview

12 steps

Algorithm Steps

12 total

  1. 01Start

    Major Bleeding on Anticoagulant

    Life-threatening or critical site bleeding requiring reversal

  2. 02Decision

    Identify Anticoagulant

    Which anticoagulant is the patient taking?

  3. 03Action

    Warfarin (VKA)

    Vitamin K antagonist reversal

    • Check INR
    • 4-Factor PCC 25-50 units/kg (based on INR)
    • Vitamin K 10mg IV slow infusion
    • Recheck INR in 30 min
    • Target INR <1.5
  4. 04Action

    Supportive Care (All Patients)

    Standard hemorrhage management

    • Hold anticoagulant
    • IV access, type and screen
    • Transfuse PRBCs for hemodynamic instability
    • Consider platelets if plt <50k
    • Local hemostatic measures
    • Maintain normothermia
  5. 05Decision

    Bleeding Site

    Location-specific considerations

  6. 06Warning

    Intracranial Hemorrhage

    Most urgent - rapid reversal critical

    • Door-to-reversal time critical
    • Target SBP <140 mmHg
    • Neurosurgery consultation
    • Repeat CT in 6 hours
    • ICU admission
  7. 07Action

    Reassess Response

    Check hemostasis and labs

    • Clinical bleeding assessment
    • Repeat coagulation studies
    • Consider re-dosing if ongoing bleeding
    • Plan anticoagulation resumption timing
  8. 08Outcome

    Bleeding Controlled

    Plan for anticoagulation resumption based on indication

  9. 09Action

    GI Hemorrhage

    Endoscopy when stable

    • IV PPI (pantoprazole 80mg bolus)
    • Gastroenterology consultation
    • Endoscopy within 24h (or emergent if unstable)
    • Transfuse to Hgb >7 (>8 if CAD)
  10. Path rejoins step 07Shared downstream outcome
  11. 10Action

    Other Major Bleeding

    Muscle, retroperitoneal, etc.

    • Imaging to characterize
    • Surgical/IR consultation as needed
    • Embolization if appropriate
    • Compartment syndrome monitoring
  12. Path rejoins step 07Shared downstream outcome
  13. 11Action

    Dabigatran

    Direct thrombin inhibitor reversal

    • Idarucizumab 5g IV (2x2.5g vials)
    • Full reversal within minutes
    • Can re-dose if needed
    • If unavailable: 4F-PCC 50 units/kg
    • Hemodialysis removes ~60% in 2-3h
  14. Path rejoins step 04Shared downstream outcome
  15. 12Action

    Factor Xa Inhibitors

    Apixaban, rivaroxaban, edoxaban

    • Andexanet alfa if available:
    • Low dose: 400mg bolus + 4mg/min x2h
    • High dose: 800mg bolus + 8mg/min x2h
    • If unavailable: 4F-PCC 50 units/kg
    • TXA 1g IV as adjunct
  16. Path rejoins step 04Shared downstream outcome

Guideline Source

Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

DOI: 10.1016/j.jtha.2024.07.009View Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Specific reversal agents may not be available at all centers
  • DOAC levels may not be immediately available
  • Cost considerations may influence reversal agent choice
  • Does not cover all anticoagulants (e.g., fondaparinux)

Applicable Regions

USEUGlobal

EU: Both specific reversal agents available

US: Andexanet alfa FDA-approved; idarucizumab available

Version 1Next review: 2027-01-01

Related Hematology & Oncology Pathways

Acute Hemolytic Transfusion Reaction Management

Emergency

Chemotherapy Extravasation Management

Emergency

Disseminated Intravascular Coagulation (ISTH 2025)

Diagnostic

Febrile Neutropenia Management (ASCO/IDSA 2018)

Emergency

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

Absolute Neutrophil Count (ANC)

Absolute neutrophil count from CBC for neutropenia grading

Open page

Compare

AttendMe.ai vs OpenEvidence

See how this pathway workflow compares against OpenEvidence.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Anticoagulation Reversal for Major Bleeding (ISTH 2025)?

The Anticoagulation Reversal for Major Bleeding (ISTH 2025) is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

What guideline is the Anticoagulation Reversal for Major Bleeding (ISTH 2025) based on?

This algorithm is based on Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH (DOI: 10.1016/j.jtha.2024.07.009).

What are the limitations of the Anticoagulation Reversal for Major Bleeding (ISTH 2025)?

Known limitations include: Specific reversal agents may not be available at all centers; DOAC levels may not be immediately available; Cost considerations may influence reversal agent choice; Does not cover all anticoagulants (e.g., fondaparinux). Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Anticoagulation Reversal for Major Bleeding (ISTH 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free